• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    2/14/23 4:53:51 PM ET
    $SAGA
    Blank Checks
    Finance
    Get the next $SAGA alert in real time by email
    SC 13G/A 1 tm235349-34_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No. 1)

     

    Under the Securities Exchange Act of 1934

     

     

    Sagaliam Acquisition Corp.

    (Name of Issuer)

     

     

    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

    78661R106

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the following box to designate the rule pursuant to which the Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     

     

     

      

    CUSIP No. 78661R106

     

      1.

    Names of Reporting Persons

    D. E. Shaw Valence Portfolios, L.L.C.

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
       

    (b)

     

    ¨
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    20,0001

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    20,0001

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    20,0001

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

      11.

    Percent of Class Represented by Amount in Row (9)

    2.0%2

     

      12.

    Type of Reporting Person (See Instructions)

    OO

     

     

     
     

    1 Consists of 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares.

    2 This percentage figure is based upon 976,337 shares of Class A common stock outstanding, consisting of (i) 956,337 shares of Class A common stock outstanding as of December 23, 2022 (computed using the amount of $57,380.22 deposited into the trust account for public shareholders at $0.06 per share in accordance with the Investment Management Trust Agreement dated December 20, 2021, as reported in the Issuer’s Form 8-K filed with the SEC on December 23, 2022), and (ii) 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares beneficially owned by the persons making this filing.

     

     

     

     

     

    CUSIP No. 78661R106

     

      1.

    Names of Reporting Persons

    D. E. Shaw & Co., L.L.C.

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
       

    (b)

     

    ¨
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    20,0001

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    20,0001

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    20,0001

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

      11.

    Percent of Class Represented by Amount in Row (9)

    2.0%2

     

      12.

    Type of Reporting Person (See Instructions)

    OO

     

     

     

    1 Consists of 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares. 

    2 This percentage figure is based upon 976,337 shares of Class A common stock outstanding, consisting of (i) 956,337 shares of Class A common stock outstanding as of December 23, 2022 (computed using the amount of $57,380.22 deposited into the trust account for public shareholders at $0.06 per share in accordance with the Investment Management Trust Agreement dated December 20, 2021, as reported in the Issuer’s Form 8-K filed with the SEC on December 23, 2022), and (ii) 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares beneficially owned by the persons making this filing.

     

     

     

     

    CUSIP No. 78661R106

     

      1.

    Names of Reporting Persons

    D. E. Shaw & Co., L.P.

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
       

    (b)

     

    ¨
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    20,0001

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    20,0001

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    20,0001

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

      11.

    Percent of Class Represented by Amount in Row (9)

    2.0%2

     

      12.

    Type of Reporting Person (See Instructions)

    IA, PN

     

     

     

    1 Consists of 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares. 

    2 This percentage figure is based upon 976,337 shares of Class A common stock outstanding, consisting of (i) 956,337 shares of Class A common stock outstanding as of December 23, 2022 (computed using the amount of $57,380.22 deposited into the trust account for public shareholders at $0.06 per share in accordance with the Investment Management Trust Agreement dated December 20, 2021, as reported in the Issuer’s Form 8-K filed with the SEC on December 23, 2022), and (ii) 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares beneficially owned by the persons making this filing.

     

     

     

     

    CUSIP No. 78661R106

     

      1.

    Names of Reporting Persons

    David E. Shaw

     

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
       

    (b)

     

    ¨
      3.

    SEC Use Only

     

      4.

    Citizenship or Place of Organization

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

     

    -0-

          6.

    Shared Voting Power

    20,0001

     

          7.

    Sole Dispositive Power

    -0-

     

          8.

    Shared Dispositive Power

    20,0001

     

      9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    20,0001

     

      10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

      11.

    Percent of Class Represented by Amount in Row (9)

    2.0%2

     

      12.

    Type of Reporting Person (See Instructions)

    IN

      

     

     
     

    1 Consists of 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares.

    2 This percentage figure is based upon 976,337 shares of Class A common stock outstanding, consisting of (i) 956,337 shares of Class A common stock outstanding as of December 23, 2022 (computed using the amount of $57,380.22 deposited into the trust account for public shareholders at $0.06 per share in accordance with the Investment Management Trust Agreement dated December 20, 2021, as reported in the Issuer’s Form 8-K filed with the SEC on December 23, 2022), and (ii) 20,000 shares of Class A common stock issuable upon conversion of Class B founder shares beneficially owned by the persons making this filing.

     

     

     

     

    Item 1.
      (a) Name of Issuer
       

      Sagaliam Acquisition Corp.

       
      (b) Address of Issuer's Principal Executive Offices
       

      1800 Avenue of the Stars, Suite 1475

      Los Angeles, CA 90067

       
    Item 2.
      (a) Name of Person Filing
       

      D. E. Shaw Valence Portfolios, L.L.C.
      D. E. Shaw & Co., L.L.C.
      D. E. Shaw & Co., L.P.

      David E. Shaw

       
      (b) Address of Principal Business Office or, if none, Residence
       

      The business address for each reporting person is:

      1166 Avenue of the Americas, 9th Floor

      New York, NY 10036

       
      (c) Citizenship
       

      D. E. Shaw Valence Portfolios, L.L.C. is a limited liability company organized under the laws of the state of Delaware.
      D. E. Shaw & Co., L.L.C. is a limited liability company organized under the laws of the state of Delaware.
      D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware.

      David E. Shaw is a citizen of the United States of America.

       
      (d) Title of Class of Securities
       

      Class A common stock, par value $0.0001 per share

       
      (e) CUSIP Number
       

      78661R106

       
    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable

     

    Item 4.

    Ownership

     

    As of December 31, 2022:

      

    (a) Amount beneficially owned:  
         
      D. E. Shaw Valence Portfolios, L.L.C.:

    20,000 shares

    This is composed of 20,000 shares that D. E. Shaw Valence Portfolios, L.L.C. has the right to acquire upon conversion of Class B founder shares

         
      D. E. Shaw & Co., L.L.C.:

    20,000 shares

    This is composed of 20,000 shares that D. E. Shaw Valence Portfolios, L.L.C. has the right to acquire upon conversion of Class B founder shares.

     

     

    D. E. Shaw & Co., L.P.:

     

     

    20,000 shares

    This is composed of 20,000 shares that D. E. Shaw Valence Portfolios, L.L.C. has the right to acquire upon conversion of Class B founder shares.

     

     

    David E. Shaw:

     

    20,000 shares

    This is composed of 20,000 shares that D. E. Shaw Valence Portfolios, L.L.C. has the right to acquire upon conversion of Class B founder shares.

         

    (b)Percent of class:

      D. E. Shaw Valence Portfolios, L.L.C.: 2.0%
      D. E. Shaw & Co., L.L.C.: 2.0%
      D. E. Shaw & Co., L.P.: 2.0%
      David E. Shaw: 2.0%

     

     

     

     

    (c)Number of shares to which the person has:
    (i)Sole power to vote or to direct the vote:
      D. E. Shaw Valence Portfolios, L.L.C.: -0- shares
      D. E. Shaw & Co., L.L.C.:

    -0- shares

      D. E. Shaw & Co., L.P.:

    -0- shares

      David E. Shaw:

    -0- shares

     

    (ii)Shared power to vote or to direct the vote:

      D. E. Shaw Valence Portfolios, L.L.C.: 20,000 shares
      D. E. Shaw & Co., L.L.C.: 20,000 shares
      D. E. Shaw & Co., L.P.: 20,000 shares
      David E. Shaw: 20,000 shares

     

    (iii)Sole power to dispose or to direct the disposition of:
      D. E. Shaw Valence Portfolios, L.L.C.: -0- shares
      D. E. Shaw & Co., L.L.C.:

    -0- shares

      D. E. Shaw & Co., L.P.:

    -0- shares

      David E. Shaw:

    -0- shares

     

    (iv)Shared power to dispose or to direct the disposition of:
      D. E. Shaw Valence Portfolios, L.L.C.: 20,000 shares
      D. E. Shaw & Co., L.L.C.:

    20,000 shares

      D. E. Shaw & Co., L.P.:

    20,000 shares

      David E. Shaw: 20,000 shares

     

    David E. Shaw does not own any shares directly. By virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C., and by virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the 20,000 shares as described above constituting 2.0% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 20,000 shares.

      

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

    Not Applicable

     

    Item 10. Certification

    By signing below, each of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., L.P., and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Powers of Attorney, dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, are attached hereto.

     

    Dated: February 14, 2023

     

     

      D. E. Shaw Valence Portfolios, L.L.C.
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Authorized Signatory

     

     

      D. E. Shaw & Co., L.L.C.
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Authorized Signatory

     

     

      D. E. Shaw & Co., L.P.
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Chief Compliance Officer

      

     

      David E. Shaw
       
      By: /s/ Nathan Thomas
        Nathan Thomas
        Attorney-in-Fact for David E. Shaw

     

     

    Get the next $SAGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SAGA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Sagaliam Acquisition Corp.

    25-NSE - Sagaliam Acquisition Corp (0001855351) (Subject)

    4/9/24 10:30:08 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

    8-K - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/7/24 9:38:34 AM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form 10-Q filed by Sagaliam Acquisition Corp.

    10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/6/24 9:45:42 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

    BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceuti

    5/1/24 8:30:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

    New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a Nasdaq Hearing Withdrawal letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on March 6, 2024. On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule. O

    3/7/24 9:35:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gld Sponsor Member, Llc

    3 - Sagaliam Acquisition Corp (0001855351) (Issuer)

    5/11/23 1:10:06 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Leadership Updates

    Live Leadership Updates

    View All

    SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER AND APPOINTMENT OF INDEPENDENT DIRECTORS

    New York, NY, July 28, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commissio

    7/28/23 5:00:00 PM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES RESIGNATION OF THOMAS W. NEUKRANZ AS CHIEF FINANCIAL OFFICER AND DIRECTOR

    New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that Thomas W. Neukranz, its Chief Financial Officer and member of its Board of Directors had resigned effective May 7, 2023. There were no disagreements between the Company and Mr. Neukranz on any matter related to the Company's operations, financial reporting, policies or practices. About Sagaliam Acquisition Corp. We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganizati

    5/11/23 1:01:00 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    SC 13G/A - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 1:49:11 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Sagaliam Acquisition Corp.

    SC 13G - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 12:16:06 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13D filed by Sagaliam Acquisition Corp.

    SC 13D - Sagaliam Acquisition Corp (0001855351) (Subject)

    5/11/23 1:08:27 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Financials

    Live finance-specific insights

    View All

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

    Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d

    11/20/23 9:10:00 AM ET
    $SAGA
    Blank Checks
    Finance